VYNE Therapeutics (VYNE) Non-Current Debt (2019 - 2021)

VYNE Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $33.3 million for Q1 2021.

• Quarterly Non-Current Debt rose 1.39% year-over-year to $33.3 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $33.3 million (up 1.39% YoY) and the FY2020 annual result came in at $33.2 million, up 1.37% from the prior year.
• Non-Current Debt was $33.3 million for Q1 2021 at VYNE Therapeutics, roughly flat from $33.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $33.3 million in Q1 2021 and bottomed at $32.7 million in Q4 2019.
• A 3-year average of $33.0 million and a median of $33.0 million in 2020 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2020 — Non-Current Debt gained 1.37% — and 2021, when it increased 1.39%.
• VYNE Therapeutics' Non-Current Debt stood at $32.7 million in 2019, then advanced by 1.37% to $33.2 million in 2020, then increased by 0.3% to $33.3 million in 2021.
• Business Quant data shows VYNE's Non-Current Debt at $33.3 million in Q1 2021, $33.2 million in Q4 2020, and $33.0 million in Q3 2020.